Janssen Belgium

XO1 Ltd is a biotechnology company focused on developing ichorcumab, an innovative anti-thrombin antibody designed to prevent heart attacks and strokes without the associated risk of bleeding. As a virtual company, XO1 operates without physical office or laboratory space, leveraging a network of high-quality contract research and development specialists across Europe and the United States. This model allows for effective cost management and ensures high-quality results by selecting the most suitable suppliers for specific tasks. The company's approach aims to revolutionize anticoagulant therapies, providing a safer alternative in the treatment of thromboembolic disorders.

Quanticare Technologies specializes in developing innovative healthcare technology aimed at enhancing the safety and well-being of seniors. The company has created a sensor system specifically designed for walking frames, which helps prevent falls among elderly users. Additionally, Quanticare's platform facilitates the monitoring and tracking of health conditions, emphasizing proactive healthcare management. By enabling patients to collect and analyze their health data, the company empowers individuals to preemptively address potential health issues and engage healthcare practitioners before complications arise. Through its commitment to improving patient outcomes, Quanticare Technologies plays a vital role in advancing senior healthcare solutions.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany, specializing in innovative therapeutics and diagnostics for heart and vascular diseases. The company is dedicated to addressing unmet medical needs in the field of cardiovascular health. Corimmun's expertise encompasses the entire process of drug development, from initial research through to commercialization. By focusing on novel treatment options, Corimmun aims to improve outcomes for patients suffering from cardiovascular conditions.

Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing small-molecule therapies for serious diseases. Its pipeline covers viral diseases, cystic fibrosis, inflammation and autoimmune disorders, cancer, and pain, with efforts to commercialize products independently and in collaboration with other pharmaceutical companies. In addition to traditional small molecules, Vertex is pursuing gene-editing therapies and non-opioid pain treatments, and it conducts research into APOL1-associated kidney diseases and cell therapies.